CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 329 enrolled
Drug / intervention
MEDI528 30 mg +3 morebiological
Likely dose
MEDI528 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00968669
NCT00968669Phase 2Completed
CompareCT.gov

A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults With Uncontrolled Asthma

MedImmune LLC·interventional·Posted Aug 31, 2009·Updated Jun 4, 2014

In Brief

A Phase 2 clinical trial evaluating MEDI528 30 mg, MEDI528 100 mg, and 2 other interventions for Asthma. Completed, enrolled 329 participants across 57 sites in 10 countries.

Detailed Summary

To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Brazil, Canada, Colombia, Costa Rica, Panama, Peru, Philippines, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 31, 2009
Enrollment StartDec 1, 2009
Primary CompletionNov 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.8 years ago

Interventions

MEDI528 30 mgbiological

MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

MEDI528 100 mgbiological

MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

MEDI528 300 mgbiological

MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

Placeboother

Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks